Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15203701 | 0.82 | PARP1 (0.44) | PARP1SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30109175 | 0.82 | PARP1 (0.44) | PARP1SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3254494 | 0.81 | PARP1 (0.55) | PARP1ADRA1A | |
| SCHEMBL4516849 | 0.80 | SLC6A2 (0.44) | PARP1MEN1KMT2ASMN1; SMN2SLC6A2 | |
| Bicarbonate SCHEMBL11624938 | 0.75 | HTR2C (0.44) | PARP1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7672752 | 0.75 | HTR2C (0.51) | MEN1KMT2ASMN1; SMN2SLC6A2SLC6A4 | |
| Acetic Acid SCHEMBL8435104 | 0.74 | TSHR (0.48) | MEN1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31056773 | 0.74 | CYP2C9 (0.40) | PARP1KMT2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27977978 | 0.73 | PARP1 (0.40) | PARP1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL31056891 | 0.72 | PARP1 (0.44) | PARP1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | PARP1 3070/4885MEN1 1339/4885KMT2A 1330/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | PARP1 3070/4885MEN1 1339/4885KMT2A 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.